An evidence-based appraisal of reflux disease management - The Genval Workshop Report

Gut

Volumn 44, Issue SUPPL. 2, 1999, Pages

  Dent, J ^a   Brun, J ^b   Fendrick, A M ^c   Fennerty, M B ^d   Janssens, J ^e   Kahrilas, P J ^f   Lauritsen, K ^g   Reynolds, J C ^h   Shaw, M ⁱ   Talley, N J ^j  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b Södra Hölsocentralen   (Sweden)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f NORTHWESTERN UNIVERSITY   (United States)

^g ODENSE UNIVERSITY HOSPITAL   (Denmark)

^h DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

ⁱ PARK NICOLLET INSTITUTE   (United States)

^j UNIVERSITY OF SYDNEY   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CISAPRIDE; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; OMEPRAZOLE; PEPSIN A; PROTON PUMP INHIBITOR; RANITIDINE;

ANTIREFLUX OPERATION; CONFERENCE PAPER; DISEASE SEVERITY; DRUG EFFICACY; ENDOSCOPIC BIOPSY; ENDOSCOPY; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; LONG TERM EXPOSURE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK FACTOR; STOMACH ACID; SYMPTOM; TREATMENT PLANNING;

EID: 0032998835     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.44.2008.s1     Document Type: Conference Paper

References (162)

1. Dimenäs E. Methodological aspects of evaluation of quality of life in upper gastrointestinal diseases. Scand J Gastroenterol 1993;28(suppl 199):18-21.
2. Glise H, Hallerbäck B, Johansson B. Quality-of-life assessments in the evaluation of gastroesophageal reflux and peptic ulcer disease before, during and after treatment. Scand J Gastroenterol 1995;30(suppl 208):133-5.
3. Rush DR, Stelmach WJ, Young TL, et al. Clinical effectiveness and quality of life with ranitidine vs placebo in gastroesophageal reflux disease patients: a clinical experience network (CEN) study. J Fam Pract 1995;41:126-36.
4. Glise H, Wiklund I. Measurement of the impact of heartburn and dyspepsia on quality of life. Aliment Pharmacol Ther 1997;11(suppl 2):73-7.
5. Lydeard S, Jones R. Factors affecting the decision to consult with dyspepsia: comparison of consulters and non-consulters. J Royal Coll Gen Pract 1989;39:495-8.
6. Bytzer P, Havelund T, Møller Hansen J. Interobserver variation in the endoscopic diagnosis of reflux esophagitis. Scand J Gastroenterol 1993;28:119-25.
7. Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 1996;111:85-92.
8. Lundell L, Dent J, Bennett JR, et al. Endoscopic assessment of esophagitis - clinical and functional correlates and further validation of the Los Angeles classification. Submitted.
9. 2 antagonists in the treatment of reflux oesophagitis: can physiological studies predict the response? Gut 1987;28:946-9.
10. Wiener GJ, Richter JE, Copper JB, et al. The symptom index: a clinically important parameter of ambulatory 24-hour esophageal pH monitoring. Am J Gastroenterol 1988;83:358-61.
11. Breumelhof R, Smout AJPM. The symptom sensitivity index: a valuable additional parameter in 24-hour esophageal pH recording. Am J Gastroenterol 1991;86:160-4.
12. Johnston BT, Collins JS, McFarland RJ, et al. Are esophageal symptoms reflux-related? A study of different scoring systems in a cohort of patients with heartburn. Am J Gastroenterol 1994;89:497-502.
13. Masclee AAM, de Best CAM, de Graaf R, et al. Ambulatory 24-hour pH-metry in the diagnosis of gastroesophageal reflux disease - determination of criteria and relation to endoscopy. Scand J Gastroenterol 1990;25:225-30.
14. Schindlbeck NE, Heinrich C, Konig A, et al. Optimal thresholds, sensitivity, and specificity of long-term pH-metry for the detection of gastroesophageal reflux disease. Gastroenterology 1987;93:85-90.
15. Shi G, des Varannes SB, Scarpignato C, et al. Reflux related symptoms in patients with normal oesophageal exposure to acid. Gut 1995;37:457-64.
16. Watson RG, Tham TC, Johnston BT, et al. Double-blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux - the "sensitive oesophagus." Gut 1997;40:587-90.
17. Kjellin A, Ramel S, Rössner S, et al. Gastroesophageal reflux in obese patients is not reduced by weight reduction. Scand J Gastroenterol 1996;31:1047-51.
18. Boeckxstaens GY, Tytgat GNJ. Pathophysiology, diagnosis, and treatment of gastroesophageal reflux disease. Curr Opin Gastroenterol 1996;12:365-72.
19. Sontag SJ. Rolling review: gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1993;7:293-312.
20. Waring JP, Eastwood TF, Austin JM, et al. The immediate effects of cessation of cigarette smoking on gastroesophageal reflux. Am J Gastroenterol 1989;84:1076-8.
21. Kahrilas PJ. Cigarette smoking and gastroesophageal reflux disease. Dig Dis 1992;10:61-71.
22. Becker DJ, Sinclair J, Castell DO, et al. A comparison of high and low fat meals on postprandial esophageal acid exposure. Am J Gastroenterol 1989;84:782-6.
23. Schindlbeck NE, Klauser AG, Berghammer G, et al. Three year follow up of patients with gastro-oesophageal reflux disease. Gut 1992;33:1016-19.
24. Isolauri J, Luostarinen M, Isolauri E, et al. Natural course of gastroesophageal reflux disease: 17-22 year follow-up of 60 patients. Am J Gastroenterol 1997;92:37-41.
25. Ollyo JB, Monnier P, Fontolliet C, et al. The natural history, prevalence and incidence of reflux oesophagitis. Gullet 1993;3(suppl):3-10.
26. Kuster E, Ros E, Toledo-Pimentel V, et al. Predictive factors of the long-term outcome in gastro-oesophageal reflux disease: six-year follow-up of 107 patients. Gut 1994;35:8-14.
27. Ben Rejeb M, Bouché O, Zeitoun P. Study of 47 consecutive patients with peptic esophageal stricture compared with 3880 cases of reflux esophagitis. Dig Dis Sci 1992;37:733-6.
28. Spechler SJ. Epidemiology and natural history of gastrooesophageal reflux disease. Digestion 1992;51(suppl 1):24-9.
29. Glise H. Quality of life and cost of therapy in reflux disease. Scand J Gastroenterol 1995;30(suppl 210):38-42.
30. Dimenäs E, Carlsson G, Glise H, et al. Relevance of norm values as part of the documentation of quality-of-life instruments for use in upper gastrointestinal disease. Scand J Gastroenterol 1996;31(suppl 221):8-13.
31. Lind T, Havelund T, Carlsson R, et al. The effect of omeprazole (OME) 20 mg and 10 mg daily on heartburn in patients with endoscopy negative reflux disease (ENRD) [abstract]. Gastroenterology 1995;108:A151
32. Lind T, Havelund T, Glise H, et al. Omeprazole (OME) improves quality of life (QoL) in patients with endoscopy negative reflux disease (ENRD) [abstract]. Gastroenterology 1995;108(suppl 4):A151.
33. McDougall NI, Johnston BT, Kee F, et al. Natural history of reflux oesophagitis: a 10-year follow-up of its effect on patient symptomatology and quality of life. Gut 1996;38:481-6.
34. Stacey JH, Miocevich ML, Sacks GE. The effect of ranitidine (as effervescent tablets) on the quality of life of GORD patients. Br J Clin Pract 1996;50:190-4.
35. Johannessen T, Petersen H, Kleveland PM, et al. The predictive value of history in dyspepsia. Scand J Gastroenterol 1990;25:689-97.
36. Glise H, Hallerback B, Johansson B. Quality-of-life assessments in evaluation of laparoscopic Rosetti fundoplication. Surg Endosc 1995;9:183-9.
37. Johnston BT, Gunning J, Lewis SA. Health care seeking by heartburn sufferers is associated with psychosocial factors. Am J Gastroenterol 1996;91:2500-4.
38. Glise H, Hallerbäck B, Wiklund I. Quality of life: a reflection of symptoms and concerns. Scand J Gastroenterol 1996;32(suppl 221):14-17.
39. Lucock MP, Morley S, White C, et al. Responses of consecutive patients to reassurance after gastroscopy: results of self administered questionnaire survey. BMJ 1997;315:572-5.
40. Wiklund I, Glise H, Jerndal P, et al. Endoscopy has a positive impact on quality of life in dyspepsia. Gastrointest Endosc 1998;47:449-54.
41. 2-blocker therapy or prompt endoscopy in management of dyspepsia. Lancet 1994;343:811-16.
42. Klauser AG, Schindlbeck NE, Müller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. Lancet 1990;335:205-8.
43. Carlsson R, Frison L, Lundell L, et al. Relationship between symptoms, endoscopic findings and treatment outcome in reflux esophagitis [abstract]. Gastroenterology 1996;110:A77.
44. Galmiche J-P, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 1997;11:765-73.
45. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease (GORD) in primary care - an international study of different treatment strategies with omeprazole. Eur J Gastroenterol Hepatol 1998;10:119-24.
46. Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997;32:974-9.
47. Small PK, Loudon MA, Waldron B, et al. Importance of reflux symptoms in functional dyspepsia. Gut 1995;36:189-92.
48. Locke GR, Talley NJ, Weaver AL, et al. A new questionnaire for gastroesophageal reflux disease. Mayo Clin Proc 1994;69:539-47.
49. Carlsson R, Dent J, Bolling-Sternevald E, et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol 1998;33:1023-9.
50. Carlsson R, Bolling E, Jerndal P, et al. Factors predicting response to omeprazole treatment in patients with functional dyspepsia [abstract]. Gastroenterology 1996;110:A76.
51. Talley NJ, Colin-Jones D, Koch KL, et al. Functional dyspepsia: a classification with guidelines for diagnosis and management. Gastroenterol Int 1991;4:145-60.
52. Johnsson F, Roth Y, Damgaard-Pedersen N-E, et al. Cimetidine improves GERD symptoms in patients selected by a validated GERD questionnaire. Aliment Pharmacol Ther 1993;7:81-6.
53. Robertson DAF, Aldersley MA, Shepherd H, et al. Patterns of acid reflux in complicated oesophagitis. Gut 1987;28:1484-8.
54. Johnsson L, Adloum W, Johnsson F, et al. Timing of reflux symptoms and esophageal acid exposure. Gullet 1992;2:58-62.
55. Gudmundsson K, Johnsson F, Joelsson B. The time pattern of gastroesophageal reflux. Scand J Gastroenterol 1988;23:75-9.
56. Mann SG, Murakami A, McCarroll K, et al. Low dose famotidine in the prevention of sleep disturbance caused by heartburn after an evening meal. Aliment Pharmacol Ther 1995;9:395-401.
57. Venables T, Newland R, Patel AC, et al. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997;32:965-73.
58. Green JRB. Is there such an entity as mild oesophagitis? Eur J Clin Res 1993;4:29-34.
59. Smout AJPM. Endoscopy-negative acid reflux disese. Aliment Pharmacol Ther 1997;11(suppl 2):81-5.
60. Locke GR, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted Country, Minnesota. Gastroenterology 1997;112:1448-56.
61. Lööf L, Götell P, Elfberg B. The incidence of reflux oesophagitis. Scand J Gastroenterol 1993;28:113-18.
62. Jones RH, Hungin APS, Phillips J, et al. Gastro-oesophageal reflux disease in primary care in Europe: clinical presentation and endoscopic findings. Eur J Gen Pract 1995;1:149-54.
63. Robinson M, Earnest D, Maton PN, et al. Frequent heartburn symptoms should not be ignored in subjects who self-treat with antacids [abstract]. Gastroenterology 1996;110:A241.
64. Gustavsson S, Bergström R, Erwall C, et al. Reflux esophagitis: assessment of therapy effects and observer variation by video documentation of endoscopy findings. Scand J Gastroenterol 1987;22:585-91.
65. Johnsson F, Joelsson B, Gudmundsson K, et al. Symptoms and endoscopic findings in the diagnosis of gastroesophageal reflux disease. Scand J Gastroenterol 1987;22:714-18.
66. Schindlbeck NE, Wiebecke B, Klauser AG, et al. Diagnostic value of histology in nonerosive gastro-oesophageal reflux disease. Gut 1996;39:151-4.
67. Ismail-Beigi F, Horton PF, Pope CE. Histological consequences of gastroesophageal reflux in man. Gastroenterology 1970;58:163-74.
68. Collins BJ, Elliott H, Sloan JM, et al. Oesophageal histology in reflux esophagitis. J Clin Pathol 1985;38:1265-72.
69. Armstrong D, Emde C, Inauen W, et al. Diagnostic assessment of gastroesophageal reflux disease: what is possible vs. what is practical? Hepatogastroenterology 1992;39(suppl 1):3-13.
70. Spechler SJ, Goyal RJ. The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett. Gastroenterology 1996;110:614-21.
71. Nandurkar S, Talley NJ, Martin CJ, et al. Short segment Barrett's oesophagus: prevalence, diagnosis and associations. Gut 1997;40:710-15.
72. Spechler SJ. Short and ultrashort Barrett's esophagus - what does it mean? Semin Gastrointest Dis 1997;8:59-67.
73. Spechler SJ, Zeroogian JMZ, Antonioli DA, et al. Prevalence of metaplasia at the gastro-oesophageal junction. Lancet 1994;344:1533-6.
74. Weston AP, Krmpotich PT, Cherian R, et al. Prospective long-term endoscopic and histological follow-up of short segment Barrett's esophagus: comparison with traditional long segment Barrett's esophagus. Am J Gastroenterol 1997;92:407-13.
75. Ghillebert G, Demeyere AM, Janssens J, et al. How well can quantitative 24-hour intraesophageal pH monitoring distinguish various degrees of reflux disease? Dig Dis Sci 1995;40:1317-24.
76. Kahrilas PJ, Quigley EMM. Clinical esophageal pH recording: a technical review for practice guideline development. Gastroenterology 1996;110:1982-96.
77. Klauser AG, Heinrich C, Schindlbeck NE, et al. Is long-term esophageal pH monitoring of clinical value? Am J Gastroenterol 1989;84:362-6.
78. Olden K, Triadafilopoulos G. Failure of initial 24-hour esophageal pH monitoring to predict refractoriness and intractability in reflux esophagitis. Am J Gastroenterol 1991;86:1141-6.
79. Quigley EMM. 24-hour pH monitoring for gastroesophageal reflux disease: already standard but not yet gold? Am J Gastroenterol 1992;87:1071-5.
80. Johnsson F, Joelsson B. Reproducibility of ambulatory oesophageal pH monitoring. Gut 1988;29:886-9.
81. Wiener GJ, Morgan TM, Copper JB, et al. Ambulatory 24-hour esophageal pH monitoring. Reproducibility and variability of pH parameters. Dig Dis Sci 1988;33:1127-33.
82. Orr WC. The physiology and philosophy of cause and effect. Gastroenterology 1994;107:1898-901.
83. Weusten BLAM, Roelofs JM, Akkermans LM, et al. The symptom-association probability: an improved method for symptom analysis of 24-hour esophageal pH data. Gastroenterology 1994;107:1741-5.
84. Weusten BLAM, Akkermans LMA, Vanberg-Henegouwen GP, et al. Symptom perception in gastroesophageal reflux disease is dependent on spatiotemporal reflux characteristics. Gastroenterology 1995;108:1739-44.
85. Cohen S, Harris LD. Does hiatal hernia affect competence of the gastresophageal sphincter? N Engl J Med 1971;284:1053-6.
86. Sloan S, Rademaker AW, Kahrilas PJ. Determinants of gastroesophageal junction incompetence: Hiatal hernia, lower esophageal sphincter, or both? Ann Intern Med 1992;117:977-82.
87. Petersen H. The clinical significance of hiatus hernia. Scand J Gastroenterol 1995;(suppl 211):19-20.
88. Ott DJ, Glauser SJ, Ledbetter MS, et al. Association of hiatal hernia and gastroesophageal reflux: correlation between presence and size of hiatal hernia and 24-hour pH monitoring of the esophagus. AJR Am J Roentgenol 1995;165:557-9.
89. Johnston BT, Troshinsky MB, Castell JA, et al. Comparison of barium radiology with esophageal pH monitoring in the diagnosis of gastroesophageal reflux disease. Am J Gastroenterol 1996;91:1181-5.
90. Schindlbeck NE, Klauser AG, Voderholzer WA, et al. Empiric therapy for gastroesophageal reflux disease. Arch Intern Med 1995;155:1808-12.
91. Johnsson F, Weywadt L, Solhaug JH, et al. One week omeprazole treatment in the diagnosis of gastrooesophageal reflux disease. Scand J Gastroenterol 1998;33:15-20.
92. Brun J, Bengtsson L, Sörngärd H. Diagnostic test and treatment of acid related GERD in a general practice population [abstract]. Gut 1997;41(suppl 3):A63.
93. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al. Omeprazole as a diagnostic tool in gastro-esophageal reflux disease. Am J Gastroenterol 1997;92:1997-2000.
94. Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112:1798-810.
95. Fass R, Fennerty B, Yalam JM, et al. Evaluation of the "omeprazole test" in patients with typical symptoms of gastroesophageal reflux disease (GERD) [abstract]. Gastroenterology 1997;112:A114.
96. Holloway RH, Dent J, Narielvala F, et al. Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis. Gut 1996;38:619-54.
97. Klinkenberg-Knol EC, Festen H, Jansen J, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994;121:161-7.
98. Kitchin LI, Castell DO. Rationale and efficacy of conservative therapy for gastroesophageal reflux disease. Arch Intern Med 1991;151:448-54.
99. Shay SS, Conwell DL, Mehindru V, et al. The effect of posture on gastroesophageal reflux event frequency and composition during fasting. Am J Gastroenterol 1996;91:54-60.
100. Johnson LF, DeMeester TR. Evaluation of elevation of the head of the bed, Bethanechol, and antacid foam tablets on gastroesophageal reflux. Dig Dis Sci 1981;26:673-80.
101. Harvey RF, Gordon PC, Hadley N et al. Effects of sleeping with the bed-head raised and of ranitidine in patients with severe peptic oesophagitis. Lancet 1987;ii:1200-3.
102. Pehl C, Pfeiffer A, Wendl B, et al. The effect of decaffeination of coffee on gastro-oesophageal reflux in patients with reflux disease. Aliment Pharmacol Ther 1997;11:483-6.
103. Murphy DW, Castell DO. Chocolate and heartburn: evidence of increased esophageal acid exposure after chocolate ingestion. Am J Gastroenterol 1988;83:633-6.
104. Allen ML, Mellow MH, Robinson MG, et al. The effect of raw onions on acid reflux and reflux symptoms. Am J Gastroenterol 1990;85:377-80.
105. Graham DY, Patterson DJ. Double-blind comparison of liquid antacid and placebo in the treatment of symptomatic reflux esophagitis. Dig Dis Sci 1983;28:559-63.
106. Graham DY, Lanza F, Dorsch ER. Symptomatic reflux esophagitis: a double-blind controlled comparison of antacids and alginate. Curr Ther Res 1977;22:653-8.
107. Dent J. Heartburn - lifting the veil of mythology. Med J Aust 1992;157:336-7.
108. 2-receptor antagonist (famotidine). Am J Ther 1995;2:304-13.
109. Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995;333:1106-10.
110. Gough AL, Long RG, Cooper BT, et al. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther 1996;10:529-39.
111. Bate CM, Griffin SM, Keeling PWN, et al. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther 1996;10:547-55.
112. Armstrong D. The clinical usefulness of prokinetic agents in gastro-oesophageal reflux disease. In: Lundell L, ed. The management of gastroesophageal reflux disease. London: Science Press, 1997:45-54.
113. Reynolds JC. Individualized acute treatment strategies for gastroesophageal reflux disease. Scand J Gastroenterol 1995;30(suppl 213):17-24.
114. Wesdorp ICE, Dekker W, Festen HPM. Efficacy of famotidine 20 mg twice a day versus 40 mg twice a day in the treatment of erosive or ulcerative reflux esophagitis. Dig Dis Sci 1993;38:2287-93.
115. Simon TJ, Berenson MM, Berlin RG, et al. Randomized, placebo-controlled comparison of famotidine 20 mg b.d. or 40 mg b.d. in patients with erosive oesophagitis. Aliment Pharmacol Ther 1994;8:71-9.
116. Tytgat GNJ, Nicolai JJ, Reman FC. Efficacy of different doses of cimetidine in the treatment of reflux esophagitis. A review of three large, double-blind, controlled trials. Gastroenterology 1990;99:629-34.
117. Johnson N, Boyd E, Mills J, et al. Acute treatment of reflux oesophagitis: a multi-centre trial to compare 150 mg ranitidine b.d with 300 gm ranitidine q.d.s. Aliment Pharmacol Ther 1989;3:258-66.
118. Geldof H, Hazelhoff B, Otten MH. Two different dose regimens of cisapride in the treatment of reflux oesophagitis: a double-blind comparison with ranitidine. Aliment Pharmacol Ther 1993;7:409-15.
119. van Outryve M, Vanderlinden I, Dedullen G, et al. Dose-response study with cisapride in gastroesophageal reflux disease. Curr Ther Res 1988;48:408-15.
120. Ramirez B, Richter JE. Promotility drugs in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1993;7:5-20.
121. Galmiche JP, Brandstätter G, Evreux M, et al. Combined therapy with cisapride and cimetidine in severe reflux oesophagitis: a double blind controlled trial. Gut 1988;29:675-81.
122. Cameron AJ, Zinsmeister AR, Ballard DJ, et al. Prevalence of columnar-lined (Barrett's) esophagus - comparison of population-based clinical and autopsy findings. Gastroenterology 1990;99:918-22.
123. van der Burgh A, Dees J, Hop SCJ, et al. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996;39:5-8.
124. Williamson WA, Ellis FH Jr, Gibb SP, et al. Barrett's esophagus prevalence and incidence of adenocarcinoma. Arch Intern Med 1991;151:2212-16.
125. Wright TA, Gray MR, Morris AI, et al. Cost effectiveness of detecting Barrett's cancer. Gut 1996;39:574-9.
126. Grimm I, Shaheen N, Bozymski EM. Surveillance for Barrett's esophagus: are we saving lives? Gastroenterology 1997;112:661-2.
127. Provenzale D, Kemp JA, Arora S, et al. A guide for surveillance of patients with Barrett's esophagus. Am J Gastroenterol 1994;89:670-80.
128. Ellis KK, Oehlke M, Helfand M, et al. Management of symptoms of gastroesophageal reflux disease: does endoscopy influence medical management? Am J Gastroenterol 1997;92:1472-4.
129. Kahrilas PJ. Treatment versus management of gastroesophageal reflux disease. Am J Gastroenterol 1997;92:1959-60.
130. Winters C, Spurling TJ, Chobanian SJ, et al. Barrett's esophagus: a prevalent occult complication of gastroesophageal reflux disease. Gastroenterology 1987;92:118-24.
131. Trimble KC, Douglas S, Pryde A, et al. Clinical characteristics and natural history of symptomatic but not excess gastroesophageal reflux. Dig Dis Sci 1995;40:1098-104.
132. Pace F, Manzionna G, Bollani S, et al. Natural history of reflux esophagitis: a 5-year follow-up [abstract]. Gastroenterology 1997;112:A249.
133. Labenz J, Blum AL, Bayerdörffer E, et al. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997;112:1442-7.
134. Werdmuller BFM, Loffeld RJLF. Helicobacter pylori infection has no role in the pathogenesis of reflux esophagitis. Dig Dis Sci 1997;42:103-5.
135. Lahenz J, Malfertheiner P. Helicobacter pylori in gastrooesophageal reflux disease: causal agent, independent or protective factor? Gut 1997;41:277-80.
136. Csendes A, Smok G, Cerda G, et al. Prevalence Helicobacter pylori infection in 190 control subjects and in 236 patients with gastroesophageal reflux, erosive esophagitis or Barrett's esophagus. Diseases of the Esophagus 1997;10:38-42.
137. Carlsson R, Galmiche J-P, Dent J, et al. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther 1997;11:473-82.
138. Bate CM, Richardson PD. A one year model for the cost-effectiveness of treating reflux esophagitis. Br J Med Econ 1992;2:5-11.
139. Hillman AL, Bloom BS, Fendrick AM, et al. Cost and quality effects of alternative treatments for persistent gastroesophageal reflux disease. Arch Intern Med 1992;152:1467-72.
140. Lindeberg G. Omeprazole vs. ranitidine in reflux oesophagitis in Sweden. Pharmacoeconomics 1994;5(suppl 3):27-34.
141. Fennerty MB. Medical treatment of GERD in the managed care environment. Semin Gastrointest Dis 1997;8:90-9.
142. Fennerty MB. The economics of therapy of gastroesophageal reflux disease. Gastroenterol Int 1997;10:126-30.
143. Drummond W. Comparing cost effectiveness across countries. The model of acid-related disease. Pharmacoeconomics 1994;5(suppl 3):60-7.
144. O'Brien BJ, Heyland D, Richardson WS, et al. User's guide to the medical literature. XIII. How to use an article on economic analysis of clinical practice. What are the results and will they help me in caring for patients? JAMA 1997;277:1802-6.
145. Dent J, Yeomans ND, Mackinnon M, et al. Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut 1994;35:590-8.
146. Harris RA, Kuppermann M, Richter JE. Prevention of recurrences of erosive esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition. Am J Med 1997;102:78-88.
147. Bate CM, Booth SN, Crowe JP, et al. Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Gut 1995;36:492-8.
148. Bardhan KD, Müller-Lissner S, Bigard MA, et al. Symptomatic gastroesophageal reflux disease (GERD): intermittent treatment (IT) with omeprazole (OM) and ranitidine (RAN) as a strategy for management [abstract]. Gastroenterology 1997;428:A65.
149. 2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology 1994;106:907-15.
150. Smith PM, Kerr GD, Cockel R, et al. A comparison of omeprazole and ranitidine in prevention of recurrence of benign esophageal stricture. Gastroenterology 1994;107:1312-18.
151. Tytgat GNJ. Long-term therapy for reflux esophagitis. N Engl J Med 1995;333:1148-50.
152. Tytgat GNJ, Blum AL, Verlinden M. Prognostic factors for relapse and maintenance treatment with cisapride in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995;9:271-80.
153. Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988;95:903-12.
154. Lundell L. New information relevant to long-term management of endoscopy-negative reflux disease. Aliment Pharmacol Ther 1997;11(suppl 2):93-8.
155. Lundell L, Abrahamsson H, Ruth M, et al. Long-term results of a prospective randomized comparison of total fundic wrap (Nissen-Rossetti) or semifundoplication (Toupet) for gastro-oesophageal reflux. Br J Surg 1996;83:830-5.
156. Johansson J, Johnsson F, Joelsson B, et al. Outcome 5 years after 360° fundoplication for gastro-oesophageal reflux disease. Br J Surg 1993;80:46-9.
157. Watson A, Jenkinson LR, Ball CS, et al. A more physiological alternative to total fundoplication for the surgical correction of resistant gastro-oesophageal reflux. Br J Surg 1991;78:1088-94.
158. Orringer MB, Skinner DB, Belsey RHR. Long-term results of the Mark IV operation for hiatal hernia and analyses of recurrences and their treatment. J Thoracic Cardiovasc Surg 1972;63:25-33.
159. Watson DI, Baigrie RJ, Jamieson GG. A learning curve for laparoscopic fundoplication. Ann Surg 1996;224:198-203.
160. Watson DI, Jamieson GG, Baigrie RJ, et al. Laparoscopic surgery for gastro-oesophageal reflux: beyond the learning curve. Br J Surg 1996;83:1284-7.
161. Perdikis G, Hinder RH, Lund RJ, et al. Laparoscopic Nissen fundoplication: where do we stand? Surg Laparosc Endosc 1997;1:17-21.
162. Heudebert GR, Marks R, Wilcox CM, et al. Choice of long-term strategy for the management of patients with severe esophagitis: a cost utility analysis. Gastroenterology 1997;112:1078-86.